Altimmune (NASDAQ:ALT) Upgraded to Hold at StockNews.com

Altimmune (NASDAQ:ALT - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Thursday.

• MarketBeat Week in Review – 11/4 - 11/8

Several other research firms have also recently weighed in on ALT. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright reiterated a "buy" rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday, April 3rd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Altimmune has a consensus rating of "Moderate Buy" and a consensus target price of $20.20.

Check Out Our Latest Research Report on ALT

Altimmune Price Performance

• How Altimmune Could Grab a Big Chunk of the GLP-1 Market

Shares of Altimmune stock traded down $0.00 during midday trading on Thursday, hitting $5.59. The company had a trading volume of 277,421 shares, compared to its average volume of 2,812,369. Altimmune has a 1-year low of $3.55 and a 1-year high of $11.16. The business's 50 day simple moving average is $5.12 and its two-hundred day simple moving average is $6.54. The stock has a market cap of $453.06 million, a PE ratio of -3.60 and a beta of 1.13.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the prior year, the firm earned ($0.34) EPS. On average, sell-side analysts expect that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Transactions at Altimmune

• This Small Cap Wealth Management Stock Could Provide Big Returns

In related news, CFO Gregory L. Weaver acquired 10,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were bought at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Altimmune

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC grew its position in Altimmune by 1.1% in the fourth quarter. Barclays PLC now owns 157,528 shares of the company's stock valued at $1,135,000 after acquiring an additional 1,787 shares during the period. Rafferty Asset Management LLC boosted its stake in shares of Altimmune by 1.3% in the 4th quarter. Rafferty Asset Management LLC now owns 157,750 shares of the company's stock valued at $1,137,000 after purchasing an additional 1,964 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Altimmune by 2.0% in the 4th quarter. JPMorgan Chase & Co. now owns 102,940 shares of the company's stock worth $742,000 after purchasing an additional 2,028 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Altimmune by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company's stock worth $945,000 after purchasing an additional 2,162 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock worth $247,000 after purchasing an additional 2,241 shares in the last quarter. Institutional investors own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

See Also

• Five stocks we like better than Altimmune
• 3 Best Fintech Stocks for a Portfolio Boost
• These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
• 2 Fintech Stocks to Buy Now and 1 to Avoid
• Buy the Dip? 3 Oil Stocks Poised for a Big Comeback
• How to Invest in Blue Chip Stocks
• Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Altimmune Right Now?

Before you consider Altimmune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.

While Altimmune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here